These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36209514)

  • 1. Cost-Effectiveness of Pediatric Universal Screening for Familial Hypercholesterolemia in Argentina.
    Araujo MB; Zerbino MC
    Value Health Reg Issues; 2023 Jan; 33():33-41. PubMed ID: 36209514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
    Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
    Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia].
    Oliva J; López-Bastida J; Moreno SG; Mata P; Alonso R
    Rev Esp Cardiol; 2009 Jan; 62(1):57-65. PubMed ID: 19150015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
    Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
    J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia.
    Lázaro P; Pérez de Isla L; Watts GF; Alonso R; Norman R; Muñiz O; Fuentes F; Mata N; López-Miranda J; González-Juanatey JR; Díaz-Díaz JL; Blasco AJ; Mata P
    J Clin Lipidol; 2017; 11(1):260-271. PubMed ID: 28391894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
    Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA
    Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
    Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
    J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis.
    Marquina C; Lacaze P; Tiller J; Riaz M; Sturm AC; Nelson MR; Ference BA; Pang J; Watts GF; Nicholls SJ; Zoungas S; Liew D; McNeil J; Ademi Z
    Eur Heart J; 2022 Sep; 43(34):3243-3254. PubMed ID: 34788414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
    Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
    Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
    Chen CX; Hay JW
    Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
    Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
    Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy].
    Alonso R; Fernández de Bobadilla J; Méndez I; Lázaro P; Mata N; Mata P
    Rev Esp Cardiol; 2008 Apr; 61(4):382-93. PubMed ID: 18405519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
    Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
    Simoes Correa-Galendi J; Del Pilar Estevez Diz M; Stock S; Müller D
    Appl Health Econ Health Policy; 2021 Jan; 19(1):97-109. PubMed ID: 32537695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cervical length screening and progesterone treatment to prevent spontaneous preterm delivery in Sweden.
    Wikström T; Kuusela P; Jacobsson B; Hagberg H; Lindgren P; Svensson M; Wennerholm UB; Valentin L
    Ultrasound Obstet Gynecol; 2022 Jun; 59(6):778-792. PubMed ID: 35195310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
    Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P
    Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.